Skip to Content


Hospira, Inc., et al.; Withdrawal of Approval of 12 Abbreviated New Drug Applications

Document Details

Information about this document as published in the Federal Register.

Document Statistics
Document page views are updated periodically throughout the day and are cumulative counts for this document including its time on Public Inspection. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.
Enhanced Content

Relevant information about this document from provides additional context. This information is not part of the official Federal Register document.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble


Food and Drug Administration, HHS.




The Food and Drug Administration (FDA or Agency) is withdrawing approval of 12 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.


Approval is withdrawn as of July 15, 2019.

Start Further Info


Trang Tran, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 1671, Silver Spring, MD 20993-0002, 240-402-7945,

End Further Info End Preamble Start Supplemental Information


The applicants listed in the table have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process described in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling.

Application No.DrugApplicant
ANDA 040664A-Methapred (methylprednisolone sodium succinate) for Injection USP, Equivalent to (EQ) 40 milligrams (mg) base/vialHospira, Inc., 275 North Field Dr., Building H1, Lake Forest, IL 60045.
ANDA 040665A-Methapred (methylprednisolone sodium succinate) for Injection USP, EQ 125 mg base/vialDo.
ANDA 060462Garamycin (gentamicin sulfate) Cream USP, EQ 0.1% baseSchering Corp., 2000 Galloping Hill Rd., Kenilworth, NJ 07033.
ANDA 061533Mycostatin (nystatin) Oral Suspension USP, 100,000 units/milliliter (mL)Bristol-Myers Squibb Co., P.O. Box 4500, Princeton, NJ 08543.
ANDA 071051Astramorph/PF (morphine sulfate) Injection USP, 0.5 mg/mLFresenius Kabi USA, LLC, Three Corporate Dr., Lake Zurich, IL 60047.
ANDA 071052Astramorph/PF (morphine sulfate) Injection USP, 1 mg/mLDo.
ANDA 071053Astramorph/PF (morphine sulfate) Injection USP, 1 mg/mLDo.
ANDA 075656Morphine Sulfate Extended-Release Tablets, 100 mgWatson Laboratories, Inc., Subsidiary of Teva Pharmaceuticals USA, Inc., 425 Privet Rd., Horsham, PA 19044.
ANDA 078815Oxaliplatin for Injection, 50 mg/vial and 100 mg/vialHospira, Inc.
ANDA 088119Isoniazid Tablets USP, 300 mgDuramed Pharmaceuticals, Inc., Subsidiary of Teva Pharmaceuticals USA, Inc., 400 Interpace Pky., Morris Corporate Center III, Parsippany, NJ 07054.
ANDA 088231Isoniazid Tablets USP, 100 mgDo.
ANDA 091597Gemcitabine for Injection USP, EQ 200 mg base/vial and EQ 1 gram base/vialSagent Pharmaceuticals, Inc., 1901 North Roselle Rd., Suite 450, Schaumburg, IL 60195.

Therefore, approval of the applications listed in the table, and all amendments and supplements thereto, is hereby withdrawn as of July 15, 2019. Approval of each entire application is withdrawn, including any strengths or products inadvertently missing from the table. Introduction or delivery for introduction into interstate commerce of products without approved new drug applications violates section 301(a) and (d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(a) and (d)). Drug products that are listed in the table that are in inventory on July 15, 2019, may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first.

Start Signature

Dated: June 10, 2019.

Lowell J. Schiller,

Principal Associate Commissioner for Policy.

End Signature End Supplemental Information

[FR Doc. 2019-12560 Filed 6-13-19; 8:45 am]